The historical rank and industry rank for Cerevel Therapeutics Holdings's Pretax Margin % or its related term are showing as below:
CERE's Pretax Margin % is not ranked *
in the Biotechnology industry.
Industry Median: -167.31 * Ranked among companies with meaningful Pretax Margin % only.
Cerevel Therapeutics Holdings Pretax Margin % Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Cerevel Therapeutics Holdings's Pretax Margin %
For the Biotechnology subindustry, Cerevel Therapeutics Holdings's Pretax Margin %, along with its competitors' market caps and Pretax Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Cerevel Therapeutics Holdings's Pretax Margin % Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Cerevel Therapeutics Holdings's Pretax Margin % distribution charts can be found below:
* The bar in red indicates where Cerevel Therapeutics Holdings's Pretax Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
The pretax margin, as know as pretax profit margin, is widely used to measure the operating efficiency of a company before deducting taxes.
The pretax margin is sometimes preferred over the net margin as tax expenditures can make profitability comparisons between companies misleading.
It is a useful tool to compare companies operating in the same sector and less effective when comparing companies from other sectors as each industry generally has different operating expenses and sales patterns.
The long term trend of the pretax margin is a good indicator of the competitiveness and health of the business.
Cerevel Therapeutics Holdings Pretax Margin % Related Terms
Thank you for viewing the detailed overview of Cerevel Therapeutics Holdings's Pretax Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.
Cerevel Therapeutics Holdings (Cerevel Therapeutics Holdings) Business Description
Cerevel Therapeutics Holdings Inc is dedicated to unraveling the mysteries of the brain to treat neuroscience diseases. The company is tackling neuroscience diseases with a differentiated approach that combines expertise in neurocircuitry with a focus on receptor selectivity. It has a diversified pipeline comprising five clinical-stage investigational therapies and several preclinical compounds with the potential to treat a range of neuroscience diseases, including schizophrenia, epilepsy, Parkinson's disease and substance use disorder. Cerevel Therapeutics is advancing its current research and development programs while exploring new modalities through internal research efforts, external collaborations or potential acquisitions.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
CERE has been successfully added to your 